Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · EIKO LIFESCIENCES LIMITED · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
Operates two business segments: Speciality Chemicals & Pharma Intermediates and Logistics Services. In FY26 consolidated revenue was Rs 52.71 crore with a 15.96% EBITDA margin and net profit of Rs 5.32 crore. In the quarter ended 31 March 2026 the specialty chemicals segment booked Rs 16.88 crore of revenue and Rs 1.25 crore of EBIT, while Logistics Services contributed Rs 1.46 crore of revenue and Rs 0.29 crore of EBIT. The group consolidates subsidiaries Eiko Scientific Solutions LLP and Eikovivify Logistics and associate Reflux Pharmaceuticals, and in January 2026 took a 31.68% stake in SSM Formulations Private Limited, a WHO-GMP pharmaceutical formulations manufacturer based in Hinganghat Wardha. Raw materials are by far the largest cost at 78.3% of revenue, with capex at 0.0% of revenue in FY26. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Speciality Chemicals & Pharma Intermediates, Logistics Services. Small specialty chemicals and logistics group, consolidating via subsidiaries and an associate
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY20–FY26 (all audited; no estimate years)
₹ crore · consolidated
FY20
FY25
FY26
Revenue
10
38
53
EBITDA (ex other income)
(5)
3
7
margin %
(44.0)
8.2
14.1
Owners' profit
(2)
2
4
EPS, as reported (₹)
(4.99)
1.62
3.26
ROE % · ROCE %
(325.5) · (172.4)
4.1 · 5.1
7.6 · 10.0
Debt / equity (x)
1.45
0.05
0.07
Cash from operations
—
3
2
Capex
—
(10)
0
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · EIKO LIFESCIENCES LIMITED · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
₹ crore
Q1 FY25
Q2 FY25
Q3 FY25
Q4 FY25
Q1 FY26
Q2 FY26
Q3 FY26
Q4 FY26
Revenue
11
8
7
11
11
12
12
18
Profit before tax
0
0
1
2
1
2
2
2
Net profit
0
0
0
1
1
1
1
1
EPS (₹)
0.29
0.22
0.32
0.80
0.66
0.78
0.88
0.93
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
Segment
Revenue, ₹ crore
Share %
Speciality Chemicals & Pharma Intermediates
27
51.5
Logistics Services
4
8.3
Specialty Chemicals & Pharma Intermediaries
10
19.9
Specialty & Fine Chemicals
8
15.9
Logistics Business
2
4.4
Total, before eliminations
53
100.0
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
Company
M.cap ₹ cr
P/E
P/B
EV/EBITDA
ROE %
ROCE %
Rev CAGR 5y %
EBITDA m. %
PIDILITE INDUSTRIES LTD
1,42,095
53.6
12.86
37.6
22.4
28.0
14.9
28.6
SRF LTD
69,659
32.2
4.96
21.6
13.1
13.1
13.4
25.2
GUJARAT FLUOROCHEM LTD
47,075
76.8
5.95
37.4
7.3
8.7
13.5
27.7
NAVIN FLUORINE INT. LTD
43,610
55.1
10.97
39.3
16.7
16.4
23.0
37.5
AETHER INDUSTRIES LIMITED
20,905
88.6
8.51
56.8
8.9
11.4
—
33.8
DEEPAK NITRITE LTD
20,257
25.9
3.45
21.0
9.4
10.2
12.6
21.5
AARTI INDUSTRIES LTD
15,871
29.9
2.67
17.1
7.0
4.4
13.0
16.2
FINE ORGANIC IND. LTD.
15,604
35.6
5.86
25.5
15.7
20.0
15.9
28.8
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
Metric
Company
Group median
Rank
Better than
P/E (TTM)
15.4
23.1
29 of 99
71%
P/B
1.0
2.8
11 of 99
89%
ROCE
9.6
10.1
55 of 106
49%
ROE
7.6
8.1
54 of 99
46%
Debt / Equity
0.1
0.2
40 of 99
60%
EBITDA margin
13.2
15.5
60 of 99
40%
Revenue growth
62.7
24.4
12 of 94
88%
Profit growth
20.4
55.1
60 of 92
35%
Market cap
72
699
87 of 108
20%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · EIKO LIFESCIENCES LIMITED · 29 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
Next day %
5-day %
19 Oct 2026 · Promoter group Lenus Finvest acquires 1.5 lakh shares via warrant conversion
ownership changes
low
—
—
16 Oct 2026 · Eiko LifeSciences allots shares on warrant conversion to promoter
fund raising
high
—
—
12 Oct 2026 · No dematerialisation requests received in H1 FY27
22 Sept 2026 · 49th AGM proceedings of Eiko LifeSciences held on 22 Sep 2026
board shareholder meetings
low
—
—
27 Aug 2026 · 49th AGM notice and annual report dispatch - 22 Sep 2026
compliance
minimal
—
—
25 Aug 2026 · Eiko Lifesciences sets 22 September 2026 AGM through video conference
compliance
minimal
—
—
24 Aug 2026 · Eiko LifeSciences files 49th Annual Report for FY26, AGM on 22 Sept 2026
board shareholder meetings
low
—
—
24 Aug 2026 · Eiko Lifesciences 49th AGM on Sept 22 via video conferencing for FY25-26
board shareholder meetings
low
—
—
24 Aug 2026 · Independent Director Hasti Doshi resigns from Eiko Lifesciences
management changes
medium
—
—
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
